Tyra Biosciences, Inc. (TYRA) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$18.75

From 52W high−51.17%

Volume871842.00

Market cap$1.33B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$18.75

From 52W high

−51.17%

Volume

871842.00

Market cap

$1.33B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.6x

P/E (TTM)

—

RSI (14)

38.7

MomentumView details →

1D Return

+4.43%

YTD Return

−25.98%

SummaryUpdated Jun 1, 2026

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Carlsbad, California. The company went public in September 2021 and focuses on developing innovative cancer therapies designed to overcome tumor resistance mechanisms that limit the effectiveness of existing treatments. Tyra specializes in precision oncology, utilizing its proprietary SNAP platform to design targeted therapies against specific genetic mutations that drive cancer growth and resistance.

Ask drillr about Tyra Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−42.01%

ROA (TTM)

−38.75%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−34.83%

FCF YoY

−26.72%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−33.11%

EBITDA YoY

−29.80%

MomentumView details →

1D Return

+4.43%

YTD Return

−25.98%

1Y Return

+29.56%

RSI (14)

38.7

vs 50D SMA

−17.33%

vs 200D SMA

−35.59%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

14.91x

Quick Ratio

14.91x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.69

EPS Surprise

−6.17%

Beats (12Q)

7/12

Next Q EPS Est

−$0.68

Avg Surprise (4Q)

−0.38%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−148.56M

Op. CF (TTM)

−109.65M

Next earningsNov 4, 2026 →

Latest newsMore news →

Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share and pre-funded warrants for 9,078,529 shares at $22.029 each, raising about $400 million.36d ago

Tyra Biosciences announced initial results from its Phase 2 SURF302 trial of oral dabogratinib, establishing clinical proof of concept and selecting a 60 mg once-daily dose for planned registrational studies.40d ago

Similar companies

Inhibrx Biosciences, Inc.INBX ORIC Pharmaceuticals, Inc.ORIC First Tracks Biotherapeutics IncTRAX Rapport Therapeutics, Inc. Common StockRAPP Taysha Gene Therapies, Inc.TSHA Ocular Therapeutix, Inc.OCUL Find similar companies →

Latest newsMore news →

Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share and pre-funded warrants for 9,078,529 shares at $22.029 each, raising about $400 million.36d ago Tyra Biosciences announced initial results from its Phase 2 SURF302 trial of oral dabogratinib, establishing clinical proof of concept and selecting a 60 mg once-daily dose for planned registrational studies.40d ago